Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the most common genetic alterations in intrahepatic cholangiocarcinoma (IHCC), a deadly liver cancer [1][2][3][4] [5] . Mutant IDH proteins in IHCC and other malignancies acquire an abnormal enzymatic activity allowing them to convert a-ketoglutarate (aKG) to 2-hydroxyglutarate (2HG), which inhibits the activity of multiple aKG-dependent dioxygenases, and results in alterations in cell differentiation, survival, and extracellular matrix maturation [6] [7] [8] [9] [10] . However, the molecular pathways by which IDH mutations lead to tumour formation remain unclear. Here we show that mutant IDH blocks liver progenitor cells from undergoing hepatocyte differentiation through the production of 2HG and suppression of HNF-4a, a master regulator of hepatocyte identity and quiescence. Correspondingly, genetically engineered mouse models expressing mutant IDH in the adult liver show an aberrant response to hepatic injury, characterized by HNF-4a silencing, impaired hepatocyte differentiation, and markedly elevated levels of cell proliferation. Moreover, IDH and Kras mutations, genetic alterations that co-exist in a subset of human IHCCs 4, 5 , cooperate to drive the expansion of liver progenitor cells, development of premalignant biliary lesions, and progression to metastatic IHCC. These studies provide a functional link between IDH mutations, hepatic cell fate, and IHCC pathogenesis, and present a novel genetically engineered mouse model of IDH-driven malignancy.
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Gain-of-function IDH1/IDH2 mutations occur in ,25% of IHCCs 1,3-5 , a liver malignancy that exhibits bile duct differentiation, but have not been identified in hepatocellular carcinomas (HCCs), which exhibit hepatocyte differentiation (http://www.sanger.ac.uk/cosmic). To examine the role of IDH mutations in liver tumorigenesis we isolated mouse hepatoblasts, which are embryonic progenitors that give rise to hepatocytes and bile duct cells and correspond with adult liver progenitors 11, 12 . Hepatoblasts expressing mutant IDH1 (R132C, R132H) or IDH2 (R140Q, R172K) produced increased 2HG, but exhibited morphology and proliferation rates indistinguishable from vector and IDH wild-type controls (Extended Data Fig. 1a-d) . However, unlike control hepatoblasts, which underwent hepatocyte differentiation when transferred from collagen-coated plates to uncoated plates 13 , forming hepatocyte clusters, decreasing proliferation, and activating a large program of hepatocytespecific genes including Adh1 and Aldob, IDH-mutant cells were refractory to differentiation (Fig. 1a-d and Extended Data Fig. 1e-g ). IDH1 (R132C) and IDH2(R172K) caused the most pronounced effects, correlating with relative 2HG levels. Treatment of R132C-expressing hepatoblasts with AGI-5027 (also known as ML309), a specific inhibitor of mutant IDH1 (ref. 14) , attenuated 2HG production (Extended Data Fig. 1h ) and restored hepatocyte differentiation (Fig. 1e, f) . Conversely, differentiation of wild-type hepatoblasts was counteracted by (R)-or (S)-2HG octyl esters (Extended Data Fig. 1i, j) . In contrast to the complete inhibition of hepatocyte differentiation, mutant IDH did not impair biliary differentiation of hepatoblasts in matrigel ( Fig. 1g and Extended Data Fig. 1k, l) . Thus, mutant IDH specifically blocks hepatocyte lineage progression through 2HG production.
To uncover the molecular program underlying these defects, we examined the effect of mutant IDH1/2 on the transcriptome of hepatoblasts grown on collagen. Transcriptional profiles of mutant IDH1 and 2 clustered together and gene set enrichment analysis (GSEA) demonstrated reduced expression of targets of HNF-4a-a master transcriptional regulator of hepatocyte differentiation 12 -and of HNF-1a, which acts downstream of HNF-4a 15 . Moreover, canonical HNF-4a-and HNF1a-binding sites were strongly enriched at the promoters of differentially expressed genes ( Fig. 2a and Extended Data Fig. 2a-c) .
HNF-4a has multiple isoforms expressed from separate promoters. The P2 promoter (encoding HNF-4a (7) (8) (9) ) is active in hepatoblasts and gradually extinguished in adult hepatocytes, whereas the P1 promoter (encoding HNF-4a(1-6)) is hepatocyte-specific 16 . Hnf4a(7-9) messenger RNA and protein were reduced in IDH-mutant hepatoblasts, as was expression of HNF-4a targets (Extended Data Fig. 2d-g ). Moreover, under hepatocyte differentiation conditions, mutant IDH completely inhibited the pronounced induction of HNF-4a(1-6) and its target-OCLN-that is observed in control cells ( Fig. 2b and Extended Data Fig. 2h) . Mutant IDH or octyl-2HG treatment blocked Hnf4a(1-6) mRNA induction, whereas AGI-5027 restored Hnfa(1-6) levels in R132C-expressing cells (Fig. 2c and Extended Data Fig. 2i-k) . Histone H3 lysine 4 trimethylation (H3K4me3) is associated with active transcription and was specifically reduced at the P1 promoter in R132C hepatoblasts, consistent with the observed silencing of Hnf4a(1-6), whereas the repressive marks, H3K27me3 and H3K9me3, were unaffected (Extended Data  Fig. 2l , m and data not shown). Importantly, HNF-4a knockdown impaired hepatocyte differentiation of wild-type hepatoblasts without inhibiting biliary differentiation, whereas ectopic HNF-4a expression rescued differentiation of IDH-mutant cells (Fig. 2d-h and Extended Data Figs 2n, o, 3a, b). Thus, mutant IDH alters the epigenetic state of the P1 promoter-through targeting either direct regulators of the locus or more upstream factors-and prevents induction Hnf4a(1-6), thereby blocking hepatocyte lineage progression. Notably, HNF-4a and HNF-1a have critical antiproliferative and tumour suppressor functions in the adult liver [17] [18] [19] [20] , suggesting the relevance of this pathway to mutant-IDHmediated tumorigenesis and prompting us to extend our studies in vivo.
We generated transgenic mice with doxycycline-inducible expression of IDH2(R140Q) or IDH2(R172K) (Tet-R140Q, Tet-R172K strains) specifically in adult hepatocytes-R140Q was detected in virtually all hepatocytes and R172K showed more scattered expression, and liver 2HG levels were elevated (Extended Data Figs 4a-d, 5a ). Since mutant IDH blocks liver progenitors from undergoing hepatocyte differentiation in vitro, we sought to address whether it acts analogously in vivo to specifically override differentiation from a progenitor cell state, or conversely, whether it broadly alters homeostasis of mature hepatocytes. Although normally quiescent, the liver has extensive regenerative capacity after injury involving replication of mature hepatocyte and biliary cells, or activation of bipotential progenitors (oval cells) that may arise from either lineage 11, 21 . In the absence of injury, Tet-R140Q mice were healthy for up to 48 weeks, and had normal liver histology, marker expression, proliferation, and liver function (Fig. 3d , Extended Data Fig. 5b and data not shown). By contrast, pronounced defects in restoration of hepatocyte differentiation were observed in mice fed a diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidin (DDC) for 5 days and then switched to a normal diet for 3 weeks (Fig. 3a) , a protocol causing hepatocyte cell death and transient oval cell activation 21, 22 . Hepatocyte markers including HNF-4a were downregulated 3-10-fold, while biliary markers were unchanged, and proliferation was increased .40-fold relative to wild-type controls ( Fig. 3b-d) . Despite this depletion of mature hepatocytes, no changes were seen in parameters of liver function (Extended Data Fig. 5c, d and data not shown), consistent with the persistence of hepatocytes surviving short-term DDC treatment and the established capacity of reduced hepatocyte numbers to maintain normal physiology. 
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Serial analyses of wild-type and Tet-R140Q livers revealed comparable numbers of proliferating periductal HNF-4a
2

/CK19
2 oval cells at 1 week, and resolution of this population after 3 weeks (Extended Data  Fig. 6a, b and Fig. 3e, f) . However, Tet-R140Q livers exhibited prominent induction of proliferating non-periductal cells with hepatocyte morphology but reduced or absent HNF-4a expression (HNF-4a 1 and HNF-4a
2
/CK19
2 ), which persisted after 3 weeks (Fig. 3e, f and Extended Data Fig. 6a-d) . Similar but more tempered phenotypes were seen in Tet-R172K mice, consistent with focal transgene expression (Extended Data Fig. 6e, f) . Thus, mutant IDH specifically blocks restoration of hepatocyte differentiation after acute liver injury, leading to aberrant proliferation in the hepatic parenchyma. As HNF-4a levels increase in liver progenitors undergoing hepatocyte commitment 23, 24 , these proliferating HNF-4a-low/absent cells appear to be committed progenitors (derived from dedifferentiated hepatocytes or oval cells) whose differentiation to hepatocytes is subverted by mutant IDH2. The transgene was not expressed in SOX9 1 oval cells, precluding assessment of effects on these earlier progenitors.
We developed an additional transgenic strain (IDH2
R172K
) expressing human IDH2(R172K) in SOX9 1 biliary cells but not in hepatocytes ( Fig. 3g and Extended Data Fig. 7a, b) . These animals displayed normal liver histology, gene expression, and proliferation at 3 months (Extended Data Fig. 7c and data not shown). However, by 20 months of age there was pronounced accumulation of HNF-4a
2
/SOX9
1 oval cells expressing IDH2(R172K) .25 mm away from any bile duct or portal structure (zones 2/3) (Fig. 3g) . Collectively, our results suggest that mutant IDH2 abrogates differentiation of adult progenitors (activated spontaneously during ageing or by injury), specifically blocking hepatocyte lineage progression.
These findings are concordant with our observations in hepatoblasts and suggest that failed HNF-4a induction could contribute to the liver phenotypes caused by mutant IDH in vivo. In this regard, acute Hnf4a deletion in hepatocytes is reported to provoke hepatocyte differentiation defects and, upon diethylnitrosamine (DEN) treatment, oval cell accumulation and formation of tumours showing HCC and IHCC morphology 20 . To expand upon potential parallels with IDH-mutant mice, we characterized these phenotypes in further depth. Importantly, the HCC lesions in DEN-treated Hnf4a conditional knockout mice were uniformly HNF-4a 1 , indicating that they arose from cells that escaped deletion of the locus (Extended Data Fig. 8a ). By contrast, SOX9
1 oval cells and CK19
1 IHCCs were HNF-4a 2 and were never observed in DEN-treated controls (Extended Data Fig. 8b, c) . Thus, HNF-4a ablation in DEN-treated livers drives progenitor expansion and progression specifically to IHCC. These findings establish Hnf4a as an IHCC tumour suppressor and are consistent with HNF-4a acting downstream of mutant IDH in liver growth control.
The capacity of mutant IDH to silence Hnf4a and impair differentiation would be expected to confer sensitivity to transformation by additional oncogenic lesions. In this regard, IDH and KRAS mutations exist concurrently in human IHCC 4,5 and acute myeloid leukaemia 25 . Previously, we showed that Kras(G12D) expression in mouse liver causes mixed IHCC/HCC with long latency, a phenotype accelerated byTP53 deletion ) animals developing poor body condition and palpable liver tumours between 33 and 58 weeks (mean 47.3 weeks; Fig. 4a ). Multifocal liver masses with splenic invasion and peritoneal metastases were observed and demonstrated to be IHCC by histopathological analysis, CK19 staining, and lack of reactivity for the hepatocyte/HCC marker Hep Par1 (Fig. 4b ). By contrast, only one out of seven Alb-Cre;LSL-Kras G12D (Kras G12D ) mice sustained a tumour by 70 weeks (mean survival 5 81.6 weeks), and solely HCCs were detected (Extended Data Fig. 8d ). Tumour 2HG levels in IDH2
R172K
;Kras G12D mice were comparable to those in IDH-mutant human IHCC 1 (Extended Data Fig. 8e ). 
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In humans, IHCC is thought to develop from precursor lesions, including biliary intraepithelial neoplasias 2 . Aberrant oval cell proliferation also precedes liver cancer development in murine models 27 . Notably, in all IDH2
R172K
;Kras G12D mice analysed (N 5 6), the adjacent liver exhibited oval cell expansion and a graded series of biliary intraepithelial neoplasia-like lesions, which were SOX9 26 showed oval cell expansion, and biliary intraepithelial neoplasias were found in only two of eight Kras G12D ;p53 Lox/1 mice. Thus, IDH2 (R172K) and Kras(G12D) cooperatively incite activation of hepatic progenitors and multistage IHCC progression.
We present a novel genetically engineered mouse model driven by mutant IDH that exhibits the hallmarks of human IHCC. Mutant IDH blocks hepatocyte differentiation from progenitors in vitro, and regulates hepatic regeneration, progenitor cell expansion, and IHCC pathogenesis in vivo. Collectively, our findings are consistent with a model whereby mutant IDH subverts the HNF-4a-mediated hepatocyte differentiation/quiescence program in proliferating hepatocytes or bipotential progenitors, creating a persistent pre-neoplastic state primed for transformation by additional oncogenic mutations, and leading to adenocarcinoma specifically with a biliary phenotype (Fig. 4d) . While lineagetracing studies are required to fully define the impact of IDH mutations on different liver cell types, this model predicts that IDH-mutant IHCC may have progenitor-like features, and that IDH mutations occur early in disease pathogenesis as observed in glioblastoma and acute myeloid leukaemia 28, 29 . Accordingly, GSEA of human IHCCs revealed that the IDH-mutant subset (17/107 cases) have strong enrichment of a hepatic stem cell signature (Extended Data Fig. 10b) .
Defining the biological functions of mutant IDH is of immediate importance as IHCCs are resistant to current treatment. Our genetically engineered mouse model provides an autochthonous context for 'co-clinical trials' to help determine the best way to deploy IDH inhibitors and identify biomarkers of response, thereby informing clinical decision-making in this deadly disease.
METHODS SUMMARY
Cell culture. Hepatoblasts were prepared from wild-type mice at embryonic day 14 and subjected to hepatocyte and bile duct differentiation as described 13 . For proliferation assays, cells were plated in duplicate on collagen-coated or uncoated 6-well plates. Cells were trypsinized and counted by trypan-blue exclusion. Mice. Mice were housed in pathogen-free animal facilities. Studies were approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital (protocol 2005N000148). The Tet-R140Q, Tet-R172K and IDH2 R172K transgenic mice and other strains are described in Methods. For DDC experiments, mice were maintained on 200 mg ml 21 doxycycline-containing water. Mice were fed with 0.1% DDC-containing chow (F4643, Bio-serv) from days 2-7. Mice were then switched to normal chow until harvest. DEN experiments were performed as described 20 . Statistics. Results are expressed as mean 6 s.d. unless otherwise specified. Significance was analysed using two-tailed Student's t-test. A P value of less than 0.05 was considered statistically significant.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Cell culture. Hepatoblasts were prepared from wild-type mice at embryonic day 14 and immortalized by plating at clonal density 13 . Hepatoblasts were maintained in HB media (DMEM/F-12 (Gibco Life Technologies) containing 10% fetal bovine serum, 1% penicillin-streptomycin, 50 ng ml 21 epidermal growth factor, 30 ng ml 21 insulin-like growth factor II (PeproTech), 10 mg ml 21 insulin (Roche)) on plates coated with rat tail collagen (BD Biosciences) in a humidified atmosphere with 5% CO 2 at 37 uC. For IDH1 experiments, culture media was supplemented with 25 ng ml 21 of doxycycline (d9891, Sigma-Aldrich). For hepatocyte differentiation assays, 5 3 10 6 hepatoblast cells were cultured on uncoated 10 cm tissue culture dishes in HB cell medium for up to 5 days. Pictures were taken 2-5 days after plating. For bile duct differentiation (matrigel) assays, 0.5 ml of Basement Membrane Matrix (BD) was coated onto 6 cm tissue culture dishes and allowed to set for 1 h. Then 0.5 3 10 6 hepatoblast cells were added to the plate in HB cell media supplemented with 100 ng ml 21 Mice were maintained on a mixed 129SV/C57BL/6 background. Data presented include both male and female mice. All mice included in the survival analysis were euthanized when criteria for disease burden were reached. The Alb-Cre strain 30 harbours a transgene in which the mouse albumin enhancer/ promoter drives Cre recombinase. Cre activity is inefficient at birth, but leads to progressive deletion of floxed sequences in all liver lineages by 4-6 weeks of age. In the Rosa26-LSL-rtTA strain 31 , the doxycycline-responsive reverse tetracycline transactivator (rtTA) is knocked into the transcriptional start site at the ubiquitously expressed Rosa26 locus and is preceded by a lox-stop-lox (LSL) casette. The LSLKras G12D strain 26 consists of a mutant Kras G12D allele knocked into the endogenous Kras locus, preceded by an LSL cassette. For IDH-mutant transgenic mouse models, transgenic mice were generated as follows. The R140Q and R172K mutations were introduced into human IDH2 cDNA (Origene, MD # SC319226, NCBI RefSeq accession number NM_002168.3) using the Quickchange kit (Agilent Lexington, MA #200521) as per the manufacturer's instructions. Two different transgenic targeting approaches were used. The first was used to generate doxycycline-inducible models. To generate the doxycycline-inducible Tet-R140Q and Tet-R172K strains (Extended Data Fig. 4), IDH2 R140Q cDNA was cloned into the pBS31 Prime transgenic targeting vector (Thermo Scientific Open Biosystems, #MES4487). A modified version of pBS31 containing a floxed stop cassette was used for the Tet-R172K mice. The targeting vectors were co-electroporated into C2 mouse embryonic stem cells (Thermo Scientific Open Biosystems, #MES4305) with a plasmid expressing FLPE recombinase (pCAGGS-FlpE, Thermo Scientific Open Biosystems, #MES4488) as described 32 . This system involves single copy integration of the transgene downstream of the collagen-1 locus, and within the liver, results in expression in hepatocytes but not in bile ducts 32 . Embryonic stem (ES) cells were screened for integration of the transgene by PCR and correctly targeted ES cells were injected into C57BL/6 blastocysts. Chimeras were crossed to the Alb-Cre strain 30 , and offspring were successively crossed with Rosa26-LSL-rtTA 31 and LSL-Kras G12D mice 26 . We confirmed the expected expression of the R140Q (Extended Data Fig. 4b, c) and R172K transgenes (Extended Data Fig. 4d ) in the adult hepatocytes and lack of expression in bile ducts.
The second approach was the stably expressed model. To generate mice with a conditionally active IDH2 R172K allele (LSL-IDH2 R172K ), human IDH2 R172K was cloned into a modified version of the PGK-ATG-Frt vector (Open Biosystems, #MES4490) containing the CAGGS promoter for stable expression (Extended Data Fig. 7a ) 33 . Gene targeting and chimaeric mouse generation was carried out as described earlier. This strain was successively crossed with Alb-Cre and LSL-Kras G12D animals. This transgene was specifically expressed in bile ducts and oval cells (Fig. 3g and Extended Data Fig. 7b ). We did not observe developmental anomalies in these mice, although the inefficiency of recombination induced by the Alb-Cre strain in neonates and the restricted activity of the transgene in this system precludes definitive assessment of potential effects of mutant IDH2 on the embryonic liver.
DDC treatment. For DDC experiments, 4-week-old mice were treated with 200 mg ml 21 doxycycline-containing water. Two days later, mice were fed with 0.1% DDC-containing chow (F4643, Bio-serv) for 5 days. The mice were then switched to normal chow and maintained on doxycycline-containing water until harvest 1 or 3 weeks later. Randomization was done according to genotype and blinding was applied during histological analysis. No mice were excluded from the analysis. Sample sizes were chosen to achieve statistical significance yet use the fewest animals possible to minimize suffering. Statistics. Results are expressed as mean 6 s.d. between two technical replicates, unless otherwise specified. Significance was analysed using two-tailed Student's t-test. A P value of less than 0.05 was considered statistically significant. Plasmids. Human wild-type IDH1 cDNA (NCBI RefSeq accession number NM_ 005896.3) was obtained from Origene and subcloned into pRetro-Puro using EcoRI and BamHI fragments. Human wild-type IDH2, R140Q and R172K cDNA (Origene) were subcloned into pRetro-puro and pMSCV-blast (derived by replacing the puromycin resistance gene from pMSCV-puro with a blasticidin resistance gene) (both from Clontech) using EcoRI and XhoI. Human IDH1 R132C was generated from wild-type IDH1 using QuikChange Lightning kit (Agilent Technologies) and primers 59-GATGGGTAAAACC TATCATCATAGGTTGTCATGCTTATGGG GATCAATAC-39 for sense and 59-GTATTGATCCCCATAAGCATGACAACC TATGATGATAGGTTTTACCCATC-39 for antisense. pLVX-Tet-On was obtained from Clontech. Murine Hnf4a was obtained from Addgene and cloned into pRetroblast (derived by replacing the puromycin resistance with blasticidin) as a BglIIEcoRI fragment. Lentiviral (pLKO.1) Hnf4a shRNA vectors TRCN0000026154, target sequence: 59-CGACAATGTGTGGTAGACAAA-39; and TRCN0000026216, target sequence: 59-GCAGATTGATGACAATGAATA-39 were used as shHnf4a#1 and shHnf4a#2, respectively, and were obtained from the Broad Institute TRC shRNA library. pLKO.1 shRNA with target sequence 59-GCAAGCTGACCCTG AAGTTCAT-39 was used as negative control shRNA. Hnf4a resistant to shHnf4a#2 was generated using QuikChange Lightning kit and primers 59-GCCCTTCCAA GAGCTGCAGA TCGACGATAACGAATATGCCTGCCTCAAAGCC-39 for sense and 59-GGCTTTGAGGCAGGCATATTCGTTATCGTCGATCTGCAGCTCTT GGAAGGGC-39 for antisense. Immunoblot analysis. Cell extracts were prepared in 13 RIPA buffer (150 mM NaCl, 1% IGEPAL, 0.1% SDS, 50 mM Tris, 0.5% DOC) supplemented with a protease inhibitor cocktail (Complete, Roche Applied Science) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail Sets I and II, Calbiochem) and quantified by BCA Protein Assay (Thermo Scientific). Thirty-micrograms protein was resolved on 9% SDS-PAGE gels and transferred onto PVDF membranes (GE Healthcare Life Sciences). Membranes were blocked in TBS with 5% non-fat milk and 0.1% Tween and probed with anti-IDH1 polyclonal antibody (3997S, Cell Signaling), anti-IDH2 polyclonal antibody (ab84726, Abcam), anti-occludin (71-1500, Invitrogen), anti-HNF-4a(126) monoclonal antibody (ab41898, Abcam), anti-HNF-4a (126)/NR2A1 monoclonal antibody (PP-K9218-00, R&D Systems), anti-HNF-4a(729) monoclonal antibody (PP-H6939-00, R&D Systems), or anti-b-actin monoclonal antibody (A5316, Sigma-Aldrich) as loading control. Bound proteins were detected with horseradish-peroxidase-conjugated secondary antibodies (Vector Biolaboratories) and SuperSignal West Pico Luminol/Enhancer Solution (Thermo Scientific). RNA analysis. Total cellular RNA was extracted using RNeasy Mini Kit (Qiagen). cDNA synthesis was performed with the QuantiTect Reverse Transcription Kit (Qiagen) with 1 mg total RNA. Sense and antisense for amplification of target genes included: Alb, 59-CATGCCAAATTAGTGCAGGA-39 and 59-GCTGGGGTTGT CATCTTTGT-39; Aldob, 59-TGTCTGGAGGTATGAGTGAGG-39 and 59-CTG GGTTGCCTTCTTGTTTGC-39; Adh1, 59-GTGACTTGTGTGAAACCAGGT-39 and 59-GCTACAAAAGTTGCTTTCCGGG-39; Ggt1, 59-CTTGTGCGAGGTGT TCTGC-39 and 59-GCATAGTCACCGTCTCTCCTT-39; Bgp, 59-CAAAAGGA GGCCTCTCAGAT-39 and 59-GCTGAGGGTTTGTGCTCTGT-39; Hnf4a(1-6), 59-GGTAGGGGAGAATGCGACTC-39 and 59-AAACTCCAGGGTGGTGTAG G-39; Foxm1, 59-ATCGCTACTTGACATTGGACCA-39 and 59-GATTGGGTC GTTTCTGCTGTG-39; Krt19, 59-TGCTGGATGAGCTGACTCTG-39 and 59-A ATCCACCTCCACACTGACC-39; Onecut1, 59-GGCAACGTGAGCGGTAGTT T-39 and 59-TTGCTGGGAGTTGTGAATGCT-39; Arg1, 59-TTGGGTGGATGC TCACACTG-39 and 59-GTACACGATGTCTTTGGCAGA-39; C2, 59-GGAACC CATTTGCCGACAG-39 and 59-GGCCCAAACTTTTTGTCAGAAG-39; C7, 59-GCAGGAAAGTGTTCAGCGG-39 and 59-CATGACCGTAAGTATTCCGTGA G-39; C9, 59-CATGCCGTGACCGAGTAGC-39 and 59-TCACAGAGTCCGTT GTAGAACT-39; Krt7, 59-CACCCGGAATGAGATTGCG-39 and 59-GCACGC TGGTTCTTCAAGGT-39; Sprr1a, 59-TTGTGCCCCCAAAACCAAG-39 and 59-GGCTCTGGTGCCTTAGGTTG-39; Ttr, 59-CACCAAATCGTACTGGAAGAC A-39 and 59-GTCGTTGGCTGTGAAAACCAC-39; ApoB, 59-TGGCTCTGATC CCAAATCCCT-39 and 59-GCTGCTCCTTGGCAGTATTAAA-39; Cyp3a13, 59-GACCACAAGCAGTGCTCTTTC-39 and 59-GCAGGGTATCATAGGTGGCA G-39.
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Gene expression profiling and GSEA. Gene expression of hepatoblasts expressing IDH1 wild type, IDH1 R132C, IDH2 wild type, R172K and empty vector controls (N 5 2 cultures for each condition) grown on collagen-coated plates, as well as IDH1 R132C and empty vector controls grown on uncoated plates, was evaluated using Affymetrix Mouse 430Av2 DNA microarrays (DFCI Microarray core facility). Raw expression values were processed and normalized using RMA in the R Bioconductor package. Differentially expressed genes in IDH1(R132C)-and IDH2 (R172K)-expressing hepatoblasts were identified using the signal-to-noise metric. GSEA of the expression data was used to uncover the molecular program accounting for the differentiation defects. GSEA was performed using two libraries from version 3.1 of the molecular signature database (http://www.broadinstitute.org/ gsea/msigdb/index.jsp): the c2 curated gene sets from online pathway databases, PubMed publications, knowledge of domain experts and the c3 motif gene sets. Pairwise GSEA analysis such as shown in Fig. 2a was performed by creating ranked lists of genes using the log 2 ratio of mutant IDH samples to vector or wild-type control and running GSEA in the ranked list mode. The heat map in Fig. 2a presents the gene sets that distinguish IDH1 R132C or IDH2 R172K as compared to cells expressing wild-type IDH1 or IDH2 or empty vector. Each column represents pairwise analysis of hepatoblast cells expressing mutant IDH (IDH1 R132C or IDH2 R172K) with either empty vector (left columns) or wild-type IDH (right columns) control cells for two independent replicates of each sample. All other results were obtained using GSEA to rank genes according to signal-to-noise ratio between mutant IDH samples and controls. Statistical significance for GSEA results were obtained from permuting gene sets (1,000 permutations). Gene sets of 'hepatocyte genes' for the GSEA results shown in Extended Data Fig. 1g were created from expression data from Shin, et al. 2011 24 . The expression data were downloaded from the Gene Expression Omnibus (accession number GSE28891) in series matrix form and loaded into R. Undifferentiated, differentiated hepatocytes, and primary hepatocyte samples were selected from GSE28891 (4 samples of each type for a total of 12). Within that sample subset, the normalized signal intensities were thresholded to a minimum value of 10 and features were filtered out if they had less than threefold difference between minimum and maximum values or had absolute differences less than 50 between minimum and maximum values (leaving 21,277 features out of 37,908). A t-test was performed between the undifferentiated and the combined differentiated and primary hepatocyte samples and P values from the t-test were corrected for multiple hypothesis testing using the Benjamini-Hochberg correction (in R using the Bioconductor multtest package). This left 206 features up and 407 down in the hepatocyte direction with an adjusted Benjamini-Hochberg P-value , 0.01, which are represented by 133 and 311 unique gene symbols, respectively. Ninetysix of these genes were represented on the murine Affymetrix array. The feature list was made into a gene set labelled as 'hepatocyte genes' and is shown in Supplementary Table 1 . Chromatin immunoprecipitation. 5 3 10 6 empty vector, IDH1 wild-type or R132C-expressing hepatoblasts were transferred from collagen-coated to uncoated plates for 5 days and fixed in 1% formaldehyde for 10 min at 37 uC. Crosslinking was terminated by the addition of glycine at a final concentration of 125 mM for 5 min. Cells were then harvested and washed twice with ice-cold PBS. Chromatin extraction, DNA sonication, and immunoprecipitation were performed using a chromatin immunoprecipitation (ChIP) Assay Kit (17-295, Millipore) and ChIPAb1 Trimethyl-Histone H3 (Lys4) (17-614, Millipore) or Tri-Methyl-Histone H3 (Lys4) Antibody (Cell Signaling, #9727S) validated antibody. Sense and antisense for amplification of target genomic regions included: Hhex, 59-GAAGGAGCCTGAC CCTTTCC-39 and 59-ATCAGCAGCGTGCACTACTC-39; Hoxa10, 59-AACAG TAAAGCTTCGCCGGA-39 and 59-AGTTCAGAAGGTCAGCCTGC-39; Hnf4a P1, 59-AACATGGCCCTATCTTCGGG-39 and 59-AAACGCACACCGCTATG TTG-39. Histology and immunostaining. Tissue samples were fixed overnight in 4% buffered formaldehyde, and then embedded in paraffin and sectioned (5 mm thickness) by the DF/HCC Research Pathology Core. Haematoxylin and eosin staining was performed using standard methods. For immunohistochemistry, unstained slides were baked at 55 uC overnight, deparaffinized in xylenes (two treatments, 6 min each), rehydrated sequentially in ethanol (5 min in 100%, 3 min in 95%, 3 min in 75%, and 3 min in 40%), and washed for 5 min in 0.3% Triton X-100/PBS (PBST) and 3 min in water. For antigen unmasking, specimens were cooked in a 2100 Antigen Retriever (Aptum Biologics) in 13 Antigen Unmasking Solution, Citric Acid Based (H-3300, Vector Laboratories), rinsed three times with PBST, incubated for 10 min with 1% H 2 O 2 at room temperature to block endogenous peroxidase activity, washed three times with PBST, and blocked with 5% goat serum in PBST for 1 h. Primary antibodies were diluted in blocking solution as follows: anti-R172K (26163, New East Biosciences) 1:100; anti-R140Q (26165 New East Biosciences) 1:100; anti-IDH2 (NBP2-22166, Novus Biologicals) 1:100; anti-HNF-4a monoclonal antibody (PP-K9218-00, R&D Systems) 1:250; anti-CK19 (Troma3) 1:100; anti-SOX9 (ab5535, Millipore) 1:300; or anti-Ki-67 (ab15580, Abcam) 1:100, and incubated with the tissue sections at 4 uC overnight. Specimens were then washed three times for 3 min each in PBST and incubated with biotinylated secondary antibody (Vector Laboratories) in blocking solution for 1 h at room temperature. Then, specimens were washed three times in PBST and treated with ABC reagent (Vectastain ABC kit #PK-6100) for 30 min, followed by three washes for 3 min each. Finally, slides were stained for peroxidase for 3 min with the DAB (di-aminebenzidine) substrate kit (SK-4100, Vector Laboratories), washed with water and counterstained with haematoxylin. Stained slides were photographed with an Olympus DP72 microscope. For immunofluorescence studies of tissue specimens, antigen unmasking was performed in 13 Antigen Retrieval Buffer, Tris-EDTA Buffer, pH 9.0 (ab93684, Abcam), rinsed briefly with dH 2 O, washed for 5 min in PBS, followed by 5 min in 0.05% Tween-20/TBS (TBST). Specimens were then blocked using 0.5% blocking reagent (FP1020, PerkinElmer) diluted in TBS (TNB) for 1 h and incubated in primary antibodies at 4 uC overnight in TNB, followed by 3 min washes in TBST and 1 h incubation in secondary antibodies (1:400) diluted in TNB. Finally, specimens were rinsed 3 3 5 min in TBST and mounted using mounting media with DAPI (H-1500, Vectashield Vector Laboratories). For cell culture staining, samples were fixed in 4% paraformaldehyde (Fisher Scientific) in PBS for 20 min followed by washing four times in PBS. Residual paraformaldehyde was removed with three 5 min washes with 100 mM glycine in PBS. Cells were permeabilized with 0.3% Triton X-100/PBS and blocked for 30 min with blocking buffer (5% bovine serum albumin, 0.2% Triton X-100, 0.05% Tween 20, PBS). Coverslips were incubated with primary (1:100) and secondary (1:1,000) antibodies diluted in blocking buffer for 1 h and 40 min, respectively, at room temperature, and nuclei were counterstained with DAPI. Coverslips were mounted with Immu-Mount (ThermoShandon). The following primary antibodies were used: rabbit anti-SOX9 (1:500; Millipore AB5535); goat anti-HNF-4a (SC6556, 1:250; Santa Cruz). Secondary antibodies were conjugated to Alexa-488, 555 or 647 (Life Technologies). Confocal images were captured by a scanning laser confocal microscope (Nikon Eclipse Ti; Nikon) using 340 or 360 oil lenses and captured using NIS-Elements software (Nikon). Images were processed using ImageJ and Adobe Photoshop CS4. For quantification of signal intensity ratios, channel intensities of individual cells were selected from at least 60 cells per sample from at 3-5 images using the Measure RGB plugin of ImageJ and exported into Excel for further analysis. 2HG production and measurement. Octyl-2HG esters were prepared from commercially available 2HG lactones (CAS# 21461-84-7 (S-) and 53558-93-3 (R-)). Esterification of lactone with 1-octanol and EDCI (CAS# 25952-53-8), followed by opening of the lactone with lithium hydroxide in tetrahydrofuran/water, yielded the 2HG-octyl esters (free carboxylic acid) upon neutralization and chromatographic purification. The sodium salts of both octyl-2HG esters are available from Toronto Research Chemicals. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis was performed using an AB Sciex 4000 operating in negative electrospray mode. MRM data were acquired for each compound using the following transitions: 2HG (146.9/128.8 amu), 13C5-2HG (151.9/133.8 amu) and 3HMG (160.9/98.9 amu). Chromatographic separation was performed using an ion-exchange column (Bio-Rad Fast Acid Analysis, 9 mm, 7.8 3 100 mm; Bio-Rad). The flow rate was 1 ml min 21 of 0.1% formic acid in water with a total run time of 4 min. Samples were prepared as follows. Tissues were weighed out and homogenized in appropriate volumes of PBS using Tissue Lyser (Qiagen). Tenmicrolitres of homogenate were extracted by adding 200 ml of methanol with 200 ng ml 21 3HMG as internal standard. Cell pellets containing 1 3 10 6 cells each were resuspended in specified volumes of 80:20 MeOH:water, centrifuged for 10 min at 14,000 r.p.m. Thirty-microlitres of supernatant were extracted by adding 170 ml of methanol with 200 ng ml 21 13C5-2HG as internal standard. All sample types were then vortexed, centrifuged at 4,000 r.p.m. at 5 uC and 150 ml of supernatant transferred to a clean 96-well plate. The samples were dried down and reconstituted in 200 ml 0.1% formic acid in water, and 10 ml injected on a column. Human samples and genomic studies. An initial cohort of 149 formalin-fixed, paraffin-embedded (FFPE) samples was obtained from IHCC patients resected between 1995 and 2007 at three centres from the HCC Genomic Consortium: IRCCS Istituto Nazionale Tumori (Milan), Mount Sinai School of Medicine (New York), and Hospital Clinic (Barcelona). Pathological diagnosis of IHCC was confirmed by two independent liver pathologists (M.S. and S.T.). DNA and RNA extraction from human tissue, whole-genome gene-expression profiling (DASL assay, Illumina), and the Infinium FFPE restoration kit (Illumina) are extensively described elsewhere 35 . The study protocol was approved by each centre's Institutional Review Board. A total of 127 samples had available data for both gene expression and DNA copy number changes and were analysed for molecular characterization to define molecular-based classes. IDH1 and 2 mutations occurring at arginine residue 132 and 172 respectively were analysed by PCR using primers 59-GTGGCACGGTCT TCAGAGA-39 (forward primer) and 59-TGCTTAATGGGTGTAGATACCAA-39 (reverse primer), and 59-GCCCACACATTTGCACTCTA-39 (forward primer) and 59-AAGGAAAGCCACGAGACAGA-39 (reverse primer). The PCR amplifications
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were performed in a volume of 25 ml reaction mixture containing 1.5 mM MgCl 2 , 0.2 mM of each dNTP, 0.125 mM of each primer and 1 U of Platinum Taq DNA Polymerase (Invitrogen). PCR products were purified using the Qiaquick PCR purification kit (Qiagen) and sequenced using an Applied Biosystems 3700 DNA sequencer (ABI PRISM 3730XL; Applied Biosystems). Good quality Sanger sequencing data for both IDH1 and IDH2 was obtained for 107 IHCC DNA samples and has been included in all the subsequent analyses. Human GSEA. Genes, molecular pathways, and gene expression signatures associated with the classes were evaluated using GSEA for Molecular Signature Database gene sets (MSigDB, http://www.broadinstitute.org/msigdb). Data analysis was conducted using the GenePattern Analytical Toolkit 34 , whereas correlation with clinico-pathological parameters was performed with SPSS software (version 18) as previously described 35 . and Tet-R172K genetically engineered models compared to control wild-type mice, after 4 weeks of doxycycline supplementation, reveals hepatocyte-specific expression, consistent with previous models using this transgenic targeting system 36 . b, Immunofluorescence analysis of Tet-R140Q and control wild-type livers using an antibody that detects both endogenous and transgenic IDH2 expression. Note that transgenic IDH2(R140Q) is expressed in the hepatocytes that stain for HNF-4a(1-6), but not in the bile ducts that are marked by CK19. c, Immunofluorescence analysis of Tet-R140Q and control wild-type livers using an antibody that is specific to IDH2(R140Q), showing an identical pattern of transgene expression. d, Immunofluorescence analysis of Tet-R172K and control wild-type livers using an antibody that is specific to IDH2(R172K). This allele is also expressed in the hepatocytes, but shows more focal expression compared to R140Q. In b and c an antibody to total HNF-4a was used to label hepatocytes. Scale bars, 50 mm. LETTER RESEARCH
